ClinicalTrials.gg
RecruitingNCT06764316BANTAM-01Updated Oct 21, 2026

A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer

A Phase 1 interventional study of BAY 3547926 and BAY 3547922 in Hepatocellular Carcinoma, sponsored by Bayer. Recruiting at 36 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Bayer · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Updated Oct 21, 202612 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
148
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Carcinoma, Hepatocellular by Bayer — 1 open to participants now, 2 under way, none of them phase 3. Carcinoma, Hepatocellular · Bayer.

Planned enrollment
9th of 20
148 · median 117
Started
2025
the only one that year
Phase 1
4 of 34
1 open now
Registered
34th of 34
by date

Among the 34 studies in Carcinoma, Hepatocellular by Bayer, this one is the 9th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 1, and was the 34th registered.

Carcinoma, Hepatocellular

3,652 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,065 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

1 of the 34 studies in Carcinoma, Hepatocellular by Bayer is open now, in 9 countries.

By country, each count listing its studies:

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Carcinoma, Hepatocellular by Bayer, or all of them as a file.
02

Study summary

In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein called Glypican 3 (GPC3). Researchers want to find the best dose of BAY 3547926 for people with advanced HCC and look at the way the body absorbs and distributes the drug.

The study drug, BAY 3547926, delivers a radioactive agent to cancer cells. The radioactive agent emits radiations which can damage the cancer cells and cause them to die. These radiations travel a small distance, so are expected to cause little damage to surrounding healthy tissues. This is the first study of BAY 3547926 in humans.

Participants will take part in one of the 4 different parts of the study. In Part 1, participants will receive different doses of BAY 3547926 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3547926 alone in Part 2 or with other treatments in Parts 3 and 4 of the study.

During the study, the doctors and their study team will do health check-ups, take pictures (scans) of the body, collect blood and urine samples, and ask participants questions about how they are feeling and what health problems they are having.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Hepatocellular carcinoma (HCC)
  • Locally advanced HCC
  • Metastatic HCC
  • Unresectable HCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Locally advanced or and/or unresectable HCC (hepatocellular carcinoma) with histological or cytological confirmation, or non-invasive diagnosis as per American Association for the Study of Liver Diseases (AASLD) criteria in participants with a confirmed diagnosis of cirrhosis.
  • Demonstrated positive centrally confirmed GPC3 expression by immunohistochemistry (IHC) on tumor sample.
  • Disease not amenable to, or progressive disease after, curative surgery and/or locoregional therapies of established efficacy such as resection, local ablation, chemoembolization.
  • (ECOG) Performance Status (PS) of 0 or 1.
  • At least one by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to (RECIST) 1.1. as assessed by local site Investigator within 28 days prior to the start of the study treatment.
  • Adequate bone marrow and organ function

Exclusion criteria

Exclusion Criteria:

  • Fibrolamellar HCC, sarcomatoid HCC, and mixed hepatocellular/cholangiocarcinoma subtypes.
  • Participants with a history or clinical evidence of , unless they meet specific criteria
  • History of encephalopathy ≥ Grade 2 within the past 12 months
  • ascites
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    BAY 3547926

    actinium-225 labeled antibody conjugate

    Drug: BAY 3547926 · Drug: BAY 3547922 · Drug: BAY 3713391 · Drug: BAY 3713389

Interventions

  • DrugBAY 3547926

    antibody conjugate with actinium-225 label

  • DrugBAY 3547922

    antibody conjugate without actinium-225 label as preinjection

  • DrugBAY 3713391

    Radioactive imaging agent - optional preinjection

  • DrugBAY 3713389

    optional preinjection

06

What researchers measure

Primary outcomes

  1. Part 1 (dose escalation): Occurrence and severity of TEAEs

    TEAE=Treatment emergent adverse event

    Time frame: up to 60 months after first administration

  2. Part 1 (dose escalation): Recommended safe and active dose (RSAD)

    The RSAD is based on incidence of DLT and preliminary anti-tumor activity (ORR using RECIST 1.1 by Investigator assessment) informed by TITE-CRM. RSAD=Recommended safe and active dose DLT=Dose limiting toxicity ORR=Objective reponse rate RECIST=Response Evaluation Criteria in Solid Tumors TITE-CRM =Time-to-event continual reassessment method

    Time frame: up to 60 months after first administration

  3. Part 2 (dose expansion): Occurrence and severity of TEAEs

    TEAE=Treatment emergent adverse event

    Time frame: up to 60 months after first administration

  4. Part 2 (dose expansion): ORR using RECIST 1.1 by investigator assessment

    ORR=Objective reponse rate RECIST=Response Evaluation Criteria in Solid Tumors

    Time frame: up to 60 months after first administration

  5. Part 2 (dose expansion): DCR using RECIST 1.1 by investigator assessment

    DCR=Disease control rate RECIST=Response Evaluation Criteria in Solid Tumors

    Time frame: up to 60 months after first administration

  6. Part 2 (dose expansion): DoR using RECIST 1.1 by investigator assessment

    DoR=Duration of response RECIST=Response Evaluation Criteria in Solid Tumors

    Time frame: up to 60 months after first administration

  7. Part 2 (dose expansion): PFS using RECIST 1.1 by investigator assessment

    PFS=Progression free survival RECIST=Response Evaluation Criteria in Solid Tumors

    Time frame: up to 60 months after first administration

  8. Parts 3 and 4 (dose expansion in combination): Occurrence and severity of TEAEs

    TEAE=Treatment emergent adverse event

    Time frame: up to 60 months after first administration

  9. Parts 3 and 4 (dose expansion in combination): ORR using RECIST 1.1 by investigator assessment

    ORR= Objective response rate

    Time frame: up to 60 months after first administration

  10. Parts 3 and 4 (dose expansion in combination): DCR using RECIST 1.1 by investigator assessment

    DCR=Disease control rate

    Time frame: up to 60 months after first administration

  11. Parts 3 and 4 (dose expansion in combination): DoR using RECIST 1.1 by investigator assessment

    DoR=Duration of response

    Time frame: up to 60 months after first administration

  12. Parts 3 and 4 (dose expansion in combination): PFS using RECIST 1.1 by investigator assessment

    PFS=Progression free survivial

    Time frame: up to 60 months after first administration

Secondary outcomes

  1. Part 1 (dose escalation): Recommended dose level(s) based on occurrence and severity of TEAEs and DLTs, PK, immunogenicity, and preliminary anit-tumor activity (ORR using RECIST 1.1 by Investigator assessment)

    TEAE=Treatment emergent adverse event DLT=Dose limiting toxicity PK=Pharmacokinetic ORR=Objective response rate RECIST=Response Evaluation Criteria in Solid Tumors

    Time frame: up to 60 months after first administration

  2. Part 1 (dose escalation): Recommended dosing regimen based on occurrence and severity of TEAEs and DLTs, PK, immunogenicity, and preliminary anti-tumor activity (ORR using RECIST 1.1 by Investigator assessment)

    TEAE=Treatment emergent adverse event DLT=Dose limiting toxicity PK=Pharmacokinetic ORR=Objective response rate RECIST=Response Evaluation Criteria in Solid Tumors

    Time frame: up to 60 months after first administration

  3. Part 1 (dose escalation): ORR using RECIST 1.1 by investigator assessment

    ORR=Objective response rate RECIST=Response Evaluation Criteria in Solid Tumors

    Time frame: up to 60 months after first administration

  4. Part 1 (dose escalation): DCR using RECIST 1.1 by investigator assessment

    DCR=Disease control rate RECIST=Response Evaluation Criteria in Solid Tumors

    Time frame: up to 60 months after first administration

  5. Part 1 (dose escalation): DoR using RECIST 1.1 by investigator assessment

    DoR=Duration of response RECIST=Response Evaluation Criteria in Solid Tumors

    Time frame: Up to 60 months after first administration

  6. Part 1 (dose escalation): PFS using RECIST 1.1 by investigator assessment

    PFS=Progression free survival RECIST=Response Evaluation Criteria in Solid Tumors

    Time frame: up to 60 months after first administration

  7. Part 1 (dose escalation): Cmax of BAY 3547926 after a single dose and after multiple doses

    Cmax=Maximal blood concentration

    Time frame: up to 36 weeks after first administration

  8. Part 1 (dose escalation): AUC of BAY 3547926 after a single dose and after multiple doses

    AUC=Area under the blood concentration versus time curve

    Time frame: up to 36 weeks after first administration

  9. Part 1 (dose escalation): Clearance of BAY 3547926 after a single dose and after multiple doses if data allow

    PK=Pharmacokinetic

    Time frame: up to 36 weeks after first administration

  10. Part 2 (dose expansion): Recommended dose based on safety, PK, IG and markers of pharmacodynamic activity and efficacy assessments

    PK=Pharmacokinetic IG=Immunogenicity

    Time frame: up to 36 months after first administration

  11. Part 2 (dose expansion): Recommended schedule based on safety, PK, IG and markers of pharmacodynamic activity and efficacy assessments

    PK=Pharmacokinetic IG=Immunogenicity

    Time frame: up to 36 months after first administration

  12. Part 2 (dose expansion): Cmax of BAY 3547926 after a single dose and after multiple doses

    Cmax=maximal blood concentration

    Time frame: up to 36 weeks after first administration

  13. Part 2 (dose expansion): AUC of BAY 3547926 after a single dose and after multiple doses

    AUC=Area under curve of blood concentration versus time curve

    Time frame: up to 36 weeks after first administration

  14. Part 2 (dose expansion): Clearance of BAY 3547926 after single dose and after multiple doses, where applicable and if data allow

    PK=Pharmacokinetic

    Time frame: up to 36 weeks after first administration

  15. Parts 3 and 4 (dose expansion in combination): Recommended dose level(s) of BAY 3547926 based on clinical data including, but not limited to, occurrence and severity of TEAEs and DLTs, PK and IG

    TEAE=Treatment emergent adverse event DLT=Dose limiting toxicity PK=Pharmacokinetic IG=Immunogenicity

    Time frame: up to 60 months after first administration

  16. Parts 3 and 4 (dose expansion in combination): Recommended dosing regimen of BAY 3547926 based on clinical data including, but not limited to, occurrence and severity of TEAEs and DLTs, PK and IG

    TEAE=Treatment emergent adverse event DLT=Dose limiting toxicity PK=Pharmacokinetic IG=Immunogenicity

    Time frame: up to 60 months after first administration

  17. Parts 3 and 4 (dose expansion in combination): Recommended schedule of BAY 3547926 based on severity of TEAEs, PK, IG

    TEAE=Treatment emergent adverse event DLT=Dose limiting toxicity PK=Pharmacokinetic IG=Immunogenicity

    Time frame: up to 60 months after first administration

  18. Parts 3 and 4 (dose expansion in combination): Cmax of BAY 3547926 after a single dose and after multiple doses of BAY 3547926 in combination

    Cmax=maximal blood concentration

    Time frame: up to 60 months after first administration

  19. Parts 3 and 4 (dose expansion in combination): AUC of BAY 3547926 after single dose and after multiple doses of BAY 3547926 in combination

    AUC=Area under curve of blood concentration versus time curve

    Time frame: up to 60 months after first administration

  20. Parts 3 and 4 (dose expansion in combination): Clearance of BAY 3547926 after single dose and after multiple doses of BAY 3547926 in combination, where applicable and if data allow

    PK=Pharmacokinetic

    Time frame: up to 60 months after first administration

07

Study locations

28 of 36 sites recruiting
  • Dothan
    Dothan, Alabama 36303, United States
    Recruiting
  • Duarte
    Duarte, California 91010, United States
    Recruiting
  • Orlando
    Orlando, Florida 32804, United States
    Not yet recruiting
  • Nashville
    Nashville, Tennessee 37232, United States
    Not yet recruiting
  • Edegem
    Edegem, Antwerp 2650, Belgium
    Recruiting
  • Leuven
    Leuven, Flemish Brabant 3000, Belgium
    Recruiting
  • Kortrijk
    Kortrijk, West Flanders 8500, Belgium
    Recruiting
  • Brussel
    Brussels, 1200, Belgium
    Recruiting
  • Toronto
    Toronto, Ontario M5G 2C4, Canada
    Recruiting
  • Montreal
    Montreal, Quebec H2X 0C1, Canada
    Recruiting
  • Montreal
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • Sherbrooke
    Sherbrooke, Quebec J1H 5N4, Canada
    Recruiting
  • Edmonton
    Edmonton, T6G 1Z2, Canada
    Not yet recruiting
  • Xuhui District
    Xuhui, Shanghai Municipality 200032, China
    Recruiting
  • Fujian
    Fujian, 350005, China
    Not yet recruiting
  • Wuhan
    Wuhan, 430023, China
    Not yet recruiting
  • Tampere
    Tampere, Pirkanmaa 33520, Finland
    Recruiting
  • Turku
    Turku, Southwest Finland 20540, Finland
    Recruiting
  • Helsinki
    Helsinki, 00029, Finland
    Not yet recruiting
  • Montpellier
    Montpellier, Occitanie 34298, France
    Recruiting
  • Bron
    Bron, 69500, France
    Recruiting
  • Nantes
    Nantes, 44093, France
    Recruiting
  • Villejuif
    Villejuif, 94805, France
    Recruiting
  • Kashiwa
    Kashiwa, 277-8577, Japan
    Recruiting
  • Tokyo
    Tokyo, 104-0045, Japan
    Recruiting
  • Tokyo
    Tokyo, 135-8550, Japan
    Recruiting
  • Barcelona
    Barcelona, Barcelona 08908, Spain
    Recruiting
  • Madrid
    Madrid, Madrid 28050, Spain
    Recruiting
  • Barcelona
    Barcelona, 08035, Spain
    Not yet recruiting
  • Madrid
    Madrid, 28027, Spain
    Recruiting
  • Pamplona
    Pamplona, 31008, Spain
    Recruiting
  • London
    London, Greater London NW3 2QG, United Kingdom
    Recruiting
  • London
    London, Greater London W12 0HS, United Kingdom
    Recruiting
  • Glasgow
    Glasgow, Scotland G12 0YN, United Kingdom
    Recruiting
  • Sutton
    Sutton, Surrey SM2 5PT, United Kingdom
    Recruiting
  • London
    London, SE59RS, United Kingdom
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jul 2029, 53 months after the start.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 53 months is above that.

Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Jan 8, 2025
StartActual
Feb 28, 2025
Primary completionEst.
Jul 31, 2029
CompletionEst.
Aug 31, 2031
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added
Show 12 added (2 United States, 2 China, 2 France, 2 Japan, 1 Canada, 1 Finland, 1 Spain, 1 United Kingdom)
  • Orlando · Orlando, United States
  • Nashville · Nashville, United States
  • Edmonton · Edmonton, Canada
  • Fujian · Fujian, China
  • Wuhan · Wuhan, China
  • Helsinki · Helsinki, Finland
  • Bron · Bron, France
  • Nantes · Nantes, France
  • Kashiwa · Kashiwa, Japan
  • Tokyo · Tokyo, Japan
  • Barcelona · Barcelona, Spain
  • London · London, United Kingdom
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    12 sites added
    Show 12 added (2 United States, 2 China, 2 France, 2 Japan, 1 Canada, 1 Finland, 1 Spain, 1 United Kingdom)
    • Orlando · Orlando, United States
    • Nashville · Nashville, United States
    • Edmonton · Edmonton, Canada
    • Fujian · Fujian, China
    • Wuhan · Wuhan, China
    • Helsinki · Helsinki, Finland
    • Bron · Bron, France
    • Nantes · Nantes, France
    • Kashiwa · Kashiwa, Japan
    • Tokyo · Tokyo, Japan
    • Barcelona · Barcelona, Spain
    • London · London, United Kingdom

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06764316
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 8, 2025
Start date
Feb 28, 2025
Primary completion
Jul 31, 2029 (estimated)
Completion
Aug 31, 2031 (estimated)
Last update
Oct 21, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
(+)1-888-84 22937

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion